Effects of curcumin in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis.

Background Curcumin is an anti-inflammatory that is proposed to have a positive impact on patients with non-alcoholic fatty liver disease (NAFLD). We aim to assess the effects of curcumin in patients with NAFLD. Methods Clinical trials from PubMed, Scopus, the Web of Science, and Cochrane CENTRAL with variables alanine transferase, aspartate transaminase, alkaline phosphatase, glycated hemoglobin (HBA1c), BMI, waist circumference, total cholesterol, total glycerides, high-density lipoproteins, and low-density lipoproteins were included. Homogeneous and heterogeneous were analyzed under a fixed-effects model and the random-effects model, respectively. Results Fourteen clinical trials found that curcumin has no statistically significant effect on alanine transferase (MD = -2.20 [-6.03, 1.63], p = 0.26], aspartate transaminase (MD = 1.37 [-4.56, 1.81], p = 0.4), alkaline phosphatase (MD = 3.06 [-15.85, 9.73], p = 0.64), glycated hemoglobin (HBA1c), (MD = -0.06 [-0.13, 0.02], p = 0.16], and BMI (MD = 0.04 [-0.38, 0.46], p = 0.86). Curcumin reduced the waist circumference (MD = -4.87 [-8.50, -1.25], p = 0.008). Lipid profile parameters were not significant, except the total glycerides (MD = -13.22 [-24.19, -2.24], p = 0.02). Conclusions Curcumin significantly reduces total glycerides and waist circumference in NAFLD.

• Publication year

  2024

• Venue

  Canadian Liver Journal

• Publication date

  2024-02-26

• Fields of study

  Medicine

• Identifiers
  DOI 10.3138/canlivj-2023-0022PMID 38746865PMCID PMC11089474
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The Effect of Curcumin Phytosome on the Treatment of Patients with Non-alcoholic Fatty Liver Disease: A Double-Blind, Randomized, Placebo-Controlled Trial.

  2021cited by this paper
• The effects of curcumin supplementation on liver function, metabolic profile and body composition in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis of randomized controlled trials.

  2020cited by this paper
• Clinimetrics: Grading of Recommendations, Assessment, Development and Evaluation (GRADE).

  2020cited by this paper
• Effects of curcuminoids on inflammatory status in patients with non-alcoholic fatty liver disease: A randomized controlled trial.

  2020cited by this paper
• Effects of non-linear resistance training and curcumin supplementation on the liver biochemical markers levels and structure in older women with non-alcoholic fatty liver disease.

  2020cited by this paper
• A pilot study of the effect of curcumin on epigenetic changes and DNA damage among patients with non-alcoholic fatty liver disease: A randomized, double-blind, placebo-controlled, clinical trial.

  2020cited by this paper
• The effects of curcumin supplementation on liver enzymes, lipid profile, glucose homeostasis, and hepatic steatosis and fibrosis in patients with non-alcoholic fatty liver disease

  2019cited by this paper
• Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis

  2019cited by this paper
• Efficacy of synbiotic supplementation in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis of clinical trials: Synbiotic supplementation and NAFLD

  2019cited by this paper
• Curcumin and inflammation in non-alcoholic fatty liver disease: a randomized, placebo controlled clinical trial

  2019cited by this paper
• Effect of Phytosomal Curcumin on Circulating Levels of Adiponectin and Leptin in Patients with Non-Alcoholic Fatty Liver Disease: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.

  2019cited by this paper
• Curcuminoids plus piperine improve nonalcoholic fatty liver disease: A clinical trial

  2019cited by this paper
• The impact of turmeric or its curcumin extract on nonalcoholic fatty liver disease: a systematic review of clinical trials

  2019cited by this paper
• Effects of phytosomal curcumin on anthropometric parameters, insulin resistance, cortisolemia and non-alcoholic fatty liver disease indices: a double-blind, placebo-controlled clinical trial

  2019cited by this paper
• Nano-curcumin improves glucose indices, lipids, inflammation, and Nesfatin in overweight and obese patients with non-alcoholic fatty liver disease (NAFLD): a double-blind randomized placebo-controlled clinical trial

  2019cited by this paper
• A pilot study of the effect of phospholipid curcumin on serum metabolomic profile in patients with non-alcoholic fatty liver disease: a randomized, double-blind, placebo-controlled trial

  2019cited by this paper
• Cochrane’s risk of bias tool in the context of psychotherapy outcome research

  2018cited by this paper
• The Effects of Curcumin on Glycemic Control and Lipid Profiles Among Patients with Metabolic Syndrome and Related Disorders: A Systematic Review and Metaanalysis of Randomized Controlled Trials.

  2018cited by this paper
• Nonalcoholic Fatty Liver Disease and Mortality.

  2018cited by this paper
• Turmeric (Curcuma longa) and its major constituent (curcumin) as nontoxic and safe substances: Review

  2018cited by this paper
• Effects of turmeric and chicory seed supplementation on antioxidant and inflammatory biomarkers in patients with non-alcoholic fatty liver disease (NAFLD)

  2018cited by this paper
• Efficacy of curcumin/turmeric on liver enzymes in patients with non-alcoholic fatty liver disease: A systematic review of randomized controlled trials

  2018cited by this paper
• Comparing different non-invasive methods in assessment of the effects of curcumin on hepatic fibrosis in patients with non-alcoholic fatty liver disease

  2018cited by this paper
• NAFLD AND NASH: Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention

  2018cited by this paper
• Efficacy and Safety of Phytosomal Curcumin in Non-Alcoholic Fatty Liver Disease: A Randomized Controlled Trial

  2017cited by this paper
• Efficacy and safety of turmeric and curcumin in lowering blood lipid levels in patients with cardiovascular risk factors: a meta-analysis of randomized controlled trials

  2017cited by this paper
• Hepatic metabolic effects of Curcuma longa extract supplement in high-fructose and saturated fat fed rats

  2017cited by this paper
• Curcumin: A Review of Its’ Effects on Human Health

  2017cited by this paper
• Effects of curcumin on HDL functionality

  2017cited by this paper
• The Effects of Curcumin against the Inflammatory Response in Patients with Acute Coronary Syndrome

  2016cited by this paper
• Effects of curcumin on serum cytokine concentrations in subjects with metabolic syndrome: A post-hoc analysis of a randomized controlled trial.

  2016cited by this paper
• Curcumin Lowers Serum Lipids and Uric Acid in Subjects With Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial

  2016cited by this paper
• Treatment of Non‐alcoholic Fatty Liver Disease with Curcumin: A Randomized Placebo‐controlled Trial

  2016cited by this paper
• Current efforts and trends in the treatment of NASH.

  2015cited by this paper
• Effect of curcuminoids on oxidative stress: A systematic review and meta-analysis of randomized controlled trials

  2015cited by this paper
• Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis.

  2015cited by this paper
• Clinical approaches to non-alcoholic fatty liver disease.

  2014cited by this paper
• Lipid‐Lowering Effects of Curcumin in Patients with Metabolic Syndrome: A Randomized, Double‐Blind, Placebo‐Controlled Trial

  2014cited by this paper
• Non-alcoholic fatty liver disease: a practical approach to treatment

  2014cited by this paper
• From NAFLD to Cardiovascular Disease. Is it (Still) the Metabolic Syndrome?

  2014cited by this paper
• Proinflammatory and antiinflammatory attributes of fetuin-a: a novel hepatokine modulating cardiovascular and glycemic outcomes in metabolic syndrome.

  2014cited by this paper
• Intestinal permeability is increased in children with non-alcoholic fatty liver disease, and correlates with liver disease severity.

  2014cited by this paper
• Epidemiology and natural history of patients with NAFLD.

  2013cited by this paper
• Effects of Supplementation with Curcuminoids on Dyslipidemia in Obese Patients: A Randomized Crossover Trial

  2013cited by this paper
• Involvement of free radicals and oxidative stress in NAFLD/NASH

  2013cited by this paper
• Long-term curcumin administration protects against atherosclerosis via hepatic regulation of lipoprotein cholesterol metabolism.

  2011cited by this paper
• Nonalcoholic fatty liver disease: a review of the spectrum of disease, diagnosis, and therapy.

  2011cited by this paper
• A two-year randomized trial of obesity treatment in primary care practice.

  2011cited by this paper
• Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.

  2010cited by this paper
• Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease

  2008cited by this paper
• Curcumin as "Curecumin": from kitchen to clinic.

  2008cited by this paper
• Curcumin attenuates the expression of IL-1beta, IL-6, and TNF-alpha as well as cyclin E in TNF-alpha-treated HaCaT cells; NF-kappaB and MAPKs as potential upstream targets.

  2007cited by this paper
• Curcumin effects on blood lipid profile in a 6-month human study.

  2007cited by this paper
• Curcumin (Diferuloylmethane) Down-Regulates Expression of Cell Proliferation and Antiapoptotic and Metastatic Gene Products through Suppression of IκBα Kinase and Akt Activation

  2006cited by this paper
• Nonalcoholic fatty liver disease

  2005cited by this paper
• Dietary fructose reduces circulating insulin and leptin, attenuates postprandial suppression of ghrelin, and increases triglycerides in women.

  2004cited by this paper
• Effect of oral curcumin administration on serum peroxides and cholesterol levels in human volunteers.

  1992cited by this paper
• Reversal of aflatoxin induced liver damage by turmeric and curcumin.

  1992cited by this paper

• Effects of Turmeric and Turmeric Plus Piperine Supplementation on Lipid Profiles in Adults with Cardiometabolic Risk Conditions: A Systematic Review and Meta-Analysis of Randomized Controlled Trials Following PRISMA Guidelines

  2025cites this paper
• In Silico Study of Natural Polyphenols as Potential Metabolic Modulators in Mitigating Lipotoxicity in Non-Alcoholic Fatty Liver Disease via Thyroid Hormone Receptor Alpha Activation

  2025cites this paper
• Therapeutic potential of Akkermansia muciniphila in non-alcoholic fatty liver disease: a systematic review

  2025cites this paper
• Curcumin and Its Derivatives in Hepatology: Therapeutic Potential and Advances in Nanoparticle Formulations

  2025cites this paper
• Curcumin Supplementation as a Preventive Strategy Against Tamoxifen-Induced Nonalcoholic Fatty Liver Disease in ER+ Breast Cancer Patients: A Triple-Blind Randomized Placebo-Controlled Trial

  2025cites this paper
• Phytotherapy for non-alcoholic fatty liver disease: A review of mechanisms, efficacy, and future directions

  2025cites this paper
• Racial and Ethnic Disparities in NAFLD: Harnessing Epigenetic and Gut Microbiota Pathways for Targeted Therapeutic Approaches

  2025cites this paper
• Nutraceutical Strategies for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Path to Liver Health

  2025influential citation
• Unlocking Cholesterol Metabolism in Metabolic-Associated Steatotic Liver Disease: Molecular Targets and Natural Product Interventions

  2024cites this paper
• Hepatic Steatosis Can Be Partly Generated by the Gut Microbiota–Mitochondria Axis via 2-Oleoyl Glycerol and Reversed by a Combination of Soy Protein, Chia Oil, Curcumin and Nopal

  2024cites this paper